Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects
Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent...
Ausführliche Beschreibung
Gespeichert in:
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: The Journal of Clinical Investigation - American Society for Clinical Investigation, 2022, 132(2022), 22 |
|---|---|
| Übergeordnetes Werk: |
volume:132 ; year:2022 ; number:22 |
| Links: |
|---|
| Katalog-ID: |
DOAJ091037751 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091037751 | ||
| 003 | DE-627 | ||
| 005 | 20240413222748.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ091037751 | ||
| 035 | |a (DE-599)DOAJf322febb20a9426fac11bb1c684e29af | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Edmone Dewaeles |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. | ||
| 650 | 4 | |a Nephrology | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a Kévin Carvalho |e verfasserin |4 aut | |
| 700 | 0 | |a Sandy Fellah |e verfasserin |4 aut | |
| 700 | 0 | |a Jaewon Sim |e verfasserin |4 aut | |
| 700 | 0 | |a Nihad Boukrout |e verfasserin |4 aut | |
| 700 | 0 | |a Raphaelle Caillierez |e verfasserin |4 aut | |
| 700 | 0 | |a Hariharan Ramakrishnan |e verfasserin |4 aut | |
| 700 | 0 | |a Cynthia Van der Hauwaert |e verfasserin |4 aut | |
| 700 | 0 | |a Jhenkruthi Vijaya Shankara |e verfasserin |4 aut | |
| 700 | 0 | |a Nathalie Martin |e verfasserin |4 aut | |
| 700 | 0 | |a Noura Massri |e verfasserin |4 aut | |
| 700 | 0 | |a Agathe Launay |e verfasserin |4 aut | |
| 700 | 0 | |a Joseph K. Folger |e verfasserin |4 aut | |
| 700 | 0 | |a Clémentine de Schutter |e verfasserin |4 aut | |
| 700 | 0 | |a Romain Larrue |e verfasserin |4 aut | |
| 700 | 0 | |a Ingrid Loison |e verfasserin |4 aut | |
| 700 | 0 | |a Marine Goujon |e verfasserin |4 aut | |
| 700 | 0 | |a Matthieu Jung |e verfasserin |4 aut | |
| 700 | 0 | |a Stéphanie Le Gras |e verfasserin |4 aut | |
| 700 | 0 | |a Victoria Gomez-Murcia |e verfasserin |4 aut | |
| 700 | 0 | |a Emilie Faivre |e verfasserin |4 aut | |
| 700 | 0 | |a Julie Lemaire |e verfasserin |4 aut | |
| 700 | 0 | |a Anne Garat |e verfasserin |4 aut | |
| 700 | 0 | |a Nicolas Beauval |e verfasserin |4 aut | |
| 700 | 0 | |a Patrice Maboudou |e verfasserin |4 aut | |
| 700 | 0 | |a Viviane Gnemmi |e verfasserin |4 aut | |
| 700 | 0 | |a Jean-Baptiste Gibier |e verfasserin |4 aut | |
| 700 | 0 | |a Luc Buée |e verfasserin |4 aut | |
| 700 | 0 | |a Corinne Abbadie |e verfasserin |4 aut | |
| 700 | 0 | |a Francois Glowacki |e verfasserin |4 aut | |
| 700 | 0 | |a Nicolas Pottier |e verfasserin |4 aut | |
| 700 | 0 | |a Michael Perrais |e verfasserin |4 aut | |
| 700 | 0 | |a Rodrigo A. Cunha |e verfasserin |4 aut | |
| 700 | 0 | |a Jean-Sébastien Annicotte |e verfasserin |4 aut | |
| 700 | 0 | |a Geoffroy Laumet |e verfasserin |4 aut | |
| 700 | 0 | |a David Blum |e verfasserin |4 aut | |
| 700 | 0 | |a Christelle Cauffiez |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t The Journal of Clinical Investigation |d American Society for Clinical Investigation, 2022 |g 132(2022), 22 |w (DE-627)316004677 |w (DE-600)2018375-6 |x 15588238 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2022 |g number:22 |
| 856 | 4 | 0 | |u https://doaj.org/article/f322febb20a9426fac11bb1c684e29af |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1172/JCI152924 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1558-8238 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2022 |e 22 | ||
| author_variant |
e d ed k c kc s f sf j s js n b nb r c rc h r hr c v d h cvdh j v s jvs n m nm n m nm a l al j k f jkf c d s cds r l rl i l il m g mg m j mj s l g slg v g m vgm e f ef j l jl a g ag n b nb p m pm v g vg j b g jbg l b lb c a ca f g fg n p np m p mp r a c rac j s a jsa g l gl d b db c c cc |
|---|---|
| matchkey_str |
article:15588238:2022----::srdfliertcsrmipaiidcdehooiiynprpeanuoahwier |
| hierarchy_sort_str |
2022 |
| publishDate |
2022 |
| allfields |
(DE-627)DOAJ091037751 (DE-599)DOAJf322febb20a9426fac11bb1c684e29af DE-627 ger DE-627 rakwb eng Edmone Dewaeles verfasserin aut Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. Nephrology Medicine R Kévin Carvalho verfasserin aut Sandy Fellah verfasserin aut Jaewon Sim verfasserin aut Nihad Boukrout verfasserin aut Raphaelle Caillierez verfasserin aut Hariharan Ramakrishnan verfasserin aut Cynthia Van der Hauwaert verfasserin aut Jhenkruthi Vijaya Shankara verfasserin aut Nathalie Martin verfasserin aut Noura Massri verfasserin aut Agathe Launay verfasserin aut Joseph K. Folger verfasserin aut Clémentine de Schutter verfasserin aut Romain Larrue verfasserin aut Ingrid Loison verfasserin aut Marine Goujon verfasserin aut Matthieu Jung verfasserin aut Stéphanie Le Gras verfasserin aut Victoria Gomez-Murcia verfasserin aut Emilie Faivre verfasserin aut Julie Lemaire verfasserin aut Anne Garat verfasserin aut Nicolas Beauval verfasserin aut Patrice Maboudou verfasserin aut Viviane Gnemmi verfasserin aut Jean-Baptiste Gibier verfasserin aut Luc Buée verfasserin aut Corinne Abbadie verfasserin aut Francois Glowacki verfasserin aut Nicolas Pottier verfasserin aut Michael Perrais verfasserin aut Rodrigo A. Cunha verfasserin aut Jean-Sébastien Annicotte verfasserin aut Geoffroy Laumet verfasserin aut David Blum verfasserin aut Christelle Cauffiez verfasserin aut In The Journal of Clinical Investigation American Society for Clinical Investigation, 2022 132(2022), 22 (DE-627)316004677 (DE-600)2018375-6 15588238 nnns volume:132 year:2022 number:22 https://doaj.org/article/f322febb20a9426fac11bb1c684e29af kostenfrei https://doi.org/10.1172/JCI152924 kostenfrei https://doaj.org/toc/1558-8238 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2006 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 132 2022 22 |
| spelling |
(DE-627)DOAJ091037751 (DE-599)DOAJf322febb20a9426fac11bb1c684e29af DE-627 ger DE-627 rakwb eng Edmone Dewaeles verfasserin aut Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. Nephrology Medicine R Kévin Carvalho verfasserin aut Sandy Fellah verfasserin aut Jaewon Sim verfasserin aut Nihad Boukrout verfasserin aut Raphaelle Caillierez verfasserin aut Hariharan Ramakrishnan verfasserin aut Cynthia Van der Hauwaert verfasserin aut Jhenkruthi Vijaya Shankara verfasserin aut Nathalie Martin verfasserin aut Noura Massri verfasserin aut Agathe Launay verfasserin aut Joseph K. Folger verfasserin aut Clémentine de Schutter verfasserin aut Romain Larrue verfasserin aut Ingrid Loison verfasserin aut Marine Goujon verfasserin aut Matthieu Jung verfasserin aut Stéphanie Le Gras verfasserin aut Victoria Gomez-Murcia verfasserin aut Emilie Faivre verfasserin aut Julie Lemaire verfasserin aut Anne Garat verfasserin aut Nicolas Beauval verfasserin aut Patrice Maboudou verfasserin aut Viviane Gnemmi verfasserin aut Jean-Baptiste Gibier verfasserin aut Luc Buée verfasserin aut Corinne Abbadie verfasserin aut Francois Glowacki verfasserin aut Nicolas Pottier verfasserin aut Michael Perrais verfasserin aut Rodrigo A. Cunha verfasserin aut Jean-Sébastien Annicotte verfasserin aut Geoffroy Laumet verfasserin aut David Blum verfasserin aut Christelle Cauffiez verfasserin aut In The Journal of Clinical Investigation American Society for Clinical Investigation, 2022 132(2022), 22 (DE-627)316004677 (DE-600)2018375-6 15588238 nnns volume:132 year:2022 number:22 https://doaj.org/article/f322febb20a9426fac11bb1c684e29af kostenfrei https://doi.org/10.1172/JCI152924 kostenfrei https://doaj.org/toc/1558-8238 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2006 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 132 2022 22 |
| allfields_unstemmed |
(DE-627)DOAJ091037751 (DE-599)DOAJf322febb20a9426fac11bb1c684e29af DE-627 ger DE-627 rakwb eng Edmone Dewaeles verfasserin aut Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. Nephrology Medicine R Kévin Carvalho verfasserin aut Sandy Fellah verfasserin aut Jaewon Sim verfasserin aut Nihad Boukrout verfasserin aut Raphaelle Caillierez verfasserin aut Hariharan Ramakrishnan verfasserin aut Cynthia Van der Hauwaert verfasserin aut Jhenkruthi Vijaya Shankara verfasserin aut Nathalie Martin verfasserin aut Noura Massri verfasserin aut Agathe Launay verfasserin aut Joseph K. Folger verfasserin aut Clémentine de Schutter verfasserin aut Romain Larrue verfasserin aut Ingrid Loison verfasserin aut Marine Goujon verfasserin aut Matthieu Jung verfasserin aut Stéphanie Le Gras verfasserin aut Victoria Gomez-Murcia verfasserin aut Emilie Faivre verfasserin aut Julie Lemaire verfasserin aut Anne Garat verfasserin aut Nicolas Beauval verfasserin aut Patrice Maboudou verfasserin aut Viviane Gnemmi verfasserin aut Jean-Baptiste Gibier verfasserin aut Luc Buée verfasserin aut Corinne Abbadie verfasserin aut Francois Glowacki verfasserin aut Nicolas Pottier verfasserin aut Michael Perrais verfasserin aut Rodrigo A. Cunha verfasserin aut Jean-Sébastien Annicotte verfasserin aut Geoffroy Laumet verfasserin aut David Blum verfasserin aut Christelle Cauffiez verfasserin aut In The Journal of Clinical Investigation American Society for Clinical Investigation, 2022 132(2022), 22 (DE-627)316004677 (DE-600)2018375-6 15588238 nnns volume:132 year:2022 number:22 https://doaj.org/article/f322febb20a9426fac11bb1c684e29af kostenfrei https://doi.org/10.1172/JCI152924 kostenfrei https://doaj.org/toc/1558-8238 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2006 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 132 2022 22 |
| allfieldsGer |
(DE-627)DOAJ091037751 (DE-599)DOAJf322febb20a9426fac11bb1c684e29af DE-627 ger DE-627 rakwb eng Edmone Dewaeles verfasserin aut Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. Nephrology Medicine R Kévin Carvalho verfasserin aut Sandy Fellah verfasserin aut Jaewon Sim verfasserin aut Nihad Boukrout verfasserin aut Raphaelle Caillierez verfasserin aut Hariharan Ramakrishnan verfasserin aut Cynthia Van der Hauwaert verfasserin aut Jhenkruthi Vijaya Shankara verfasserin aut Nathalie Martin verfasserin aut Noura Massri verfasserin aut Agathe Launay verfasserin aut Joseph K. Folger verfasserin aut Clémentine de Schutter verfasserin aut Romain Larrue verfasserin aut Ingrid Loison verfasserin aut Marine Goujon verfasserin aut Matthieu Jung verfasserin aut Stéphanie Le Gras verfasserin aut Victoria Gomez-Murcia verfasserin aut Emilie Faivre verfasserin aut Julie Lemaire verfasserin aut Anne Garat verfasserin aut Nicolas Beauval verfasserin aut Patrice Maboudou verfasserin aut Viviane Gnemmi verfasserin aut Jean-Baptiste Gibier verfasserin aut Luc Buée verfasserin aut Corinne Abbadie verfasserin aut Francois Glowacki verfasserin aut Nicolas Pottier verfasserin aut Michael Perrais verfasserin aut Rodrigo A. Cunha verfasserin aut Jean-Sébastien Annicotte verfasserin aut Geoffroy Laumet verfasserin aut David Blum verfasserin aut Christelle Cauffiez verfasserin aut In The Journal of Clinical Investigation American Society for Clinical Investigation, 2022 132(2022), 22 (DE-627)316004677 (DE-600)2018375-6 15588238 nnns volume:132 year:2022 number:22 https://doaj.org/article/f322febb20a9426fac11bb1c684e29af kostenfrei https://doi.org/10.1172/JCI152924 kostenfrei https://doaj.org/toc/1558-8238 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2006 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 132 2022 22 |
| allfieldsSound |
(DE-627)DOAJ091037751 (DE-599)DOAJf322febb20a9426fac11bb1c684e29af DE-627 ger DE-627 rakwb eng Edmone Dewaeles verfasserin aut Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. Nephrology Medicine R Kévin Carvalho verfasserin aut Sandy Fellah verfasserin aut Jaewon Sim verfasserin aut Nihad Boukrout verfasserin aut Raphaelle Caillierez verfasserin aut Hariharan Ramakrishnan verfasserin aut Cynthia Van der Hauwaert verfasserin aut Jhenkruthi Vijaya Shankara verfasserin aut Nathalie Martin verfasserin aut Noura Massri verfasserin aut Agathe Launay verfasserin aut Joseph K. Folger verfasserin aut Clémentine de Schutter verfasserin aut Romain Larrue verfasserin aut Ingrid Loison verfasserin aut Marine Goujon verfasserin aut Matthieu Jung verfasserin aut Stéphanie Le Gras verfasserin aut Victoria Gomez-Murcia verfasserin aut Emilie Faivre verfasserin aut Julie Lemaire verfasserin aut Anne Garat verfasserin aut Nicolas Beauval verfasserin aut Patrice Maboudou verfasserin aut Viviane Gnemmi verfasserin aut Jean-Baptiste Gibier verfasserin aut Luc Buée verfasserin aut Corinne Abbadie verfasserin aut Francois Glowacki verfasserin aut Nicolas Pottier verfasserin aut Michael Perrais verfasserin aut Rodrigo A. Cunha verfasserin aut Jean-Sébastien Annicotte verfasserin aut Geoffroy Laumet verfasserin aut David Blum verfasserin aut Christelle Cauffiez verfasserin aut In The Journal of Clinical Investigation American Society for Clinical Investigation, 2022 132(2022), 22 (DE-627)316004677 (DE-600)2018375-6 15588238 nnns volume:132 year:2022 number:22 https://doaj.org/article/f322febb20a9426fac11bb1c684e29af kostenfrei https://doi.org/10.1172/JCI152924 kostenfrei https://doaj.org/toc/1558-8238 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2006 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 132 2022 22 |
| language |
English |
| source |
In The Journal of Clinical Investigation 132(2022), 22 volume:132 year:2022 number:22 |
| sourceStr |
In The Journal of Clinical Investigation 132(2022), 22 volume:132 year:2022 number:22 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Nephrology Medicine R |
| isfreeaccess_bool |
true |
| container_title |
The Journal of Clinical Investigation |
| authorswithroles_txt_mv |
Edmone Dewaeles @@aut@@ Kévin Carvalho @@aut@@ Sandy Fellah @@aut@@ Jaewon Sim @@aut@@ Nihad Boukrout @@aut@@ Raphaelle Caillierez @@aut@@ Hariharan Ramakrishnan @@aut@@ Cynthia Van der Hauwaert @@aut@@ Jhenkruthi Vijaya Shankara @@aut@@ Nathalie Martin @@aut@@ Noura Massri @@aut@@ Agathe Launay @@aut@@ Joseph K. Folger @@aut@@ Clémentine de Schutter @@aut@@ Romain Larrue @@aut@@ Ingrid Loison @@aut@@ Marine Goujon @@aut@@ Matthieu Jung @@aut@@ Stéphanie Le Gras @@aut@@ Victoria Gomez-Murcia @@aut@@ Emilie Faivre @@aut@@ Julie Lemaire @@aut@@ Anne Garat @@aut@@ Nicolas Beauval @@aut@@ Patrice Maboudou @@aut@@ Viviane Gnemmi @@aut@@ Jean-Baptiste Gibier @@aut@@ Luc Buée @@aut@@ Corinne Abbadie @@aut@@ Francois Glowacki @@aut@@ Nicolas Pottier @@aut@@ Michael Perrais @@aut@@ Rodrigo A. Cunha @@aut@@ Jean-Sébastien Annicotte @@aut@@ Geoffroy Laumet @@aut@@ David Blum @@aut@@ Christelle Cauffiez @@aut@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
316004677 |
| id |
DOAJ091037751 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ091037751</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413222748.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ091037751</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf322febb20a9426fac11bb1c684e29af</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Edmone Dewaeles</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nephrology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kévin Carvalho</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandy Fellah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jaewon Sim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nihad Boukrout</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Raphaelle Caillierez</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hariharan Ramakrishnan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cynthia Van der Hauwaert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jhenkruthi Vijaya Shankara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nathalie Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Noura Massri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Agathe Launay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joseph K. Folger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Clémentine de Schutter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Romain Larrue</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ingrid Loison</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marine Goujon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matthieu Jung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stéphanie Le Gras</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Victoria Gomez-Murcia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Emilie Faivre</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julie Lemaire</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anne Garat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicolas Beauval</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Patrice Maboudou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Viviane Gnemmi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jean-Baptiste Gibier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luc Buée</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Corinne Abbadie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francois Glowacki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicolas Pottier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael Perrais</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rodrigo A. Cunha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jean-Sébastien Annicotte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Geoffroy Laumet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Blum</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christelle Cauffiez</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">The Journal of Clinical Investigation</subfield><subfield code="d">American Society for Clinical Investigation, 2022</subfield><subfield code="g">132(2022), 22</subfield><subfield code="w">(DE-627)316004677</subfield><subfield code="w">(DE-600)2018375-6</subfield><subfield code="x">15588238</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:132</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:22</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f322febb20a9426fac11bb1c684e29af</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1172/JCI152924</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1558-8238</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">132</subfield><subfield code="j">2022</subfield><subfield code="e">22</subfield></datafield></record></collection>
|
| author |
Edmone Dewaeles |
| spellingShingle |
Edmone Dewaeles misc Nephrology misc Medicine misc R Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects |
| authorStr |
Edmone Dewaeles |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)316004677 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
15588238 |
| topic_title |
Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects Nephrology |
| topic |
misc Nephrology misc Medicine misc R |
| topic_unstemmed |
misc Nephrology misc Medicine misc R |
| topic_browse |
misc Nephrology misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
The Journal of Clinical Investigation |
| hierarchy_parent_id |
316004677 |
| hierarchy_top_title |
The Journal of Clinical Investigation |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)316004677 (DE-600)2018375-6 |
| title |
Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects |
| ctrlnum |
(DE-627)DOAJ091037751 (DE-599)DOAJf322febb20a9426fac11bb1c684e29af |
| title_full |
Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects |
| author_sort |
Edmone Dewaeles |
| journal |
The Journal of Clinical Investigation |
| journalStr |
The Journal of Clinical Investigation |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
txt |
| author_browse |
Edmone Dewaeles Kévin Carvalho Sandy Fellah Jaewon Sim Nihad Boukrout Raphaelle Caillierez Hariharan Ramakrishnan Cynthia Van der Hauwaert Jhenkruthi Vijaya Shankara Nathalie Martin Noura Massri Agathe Launay Joseph K. Folger Clémentine de Schutter Romain Larrue Ingrid Loison Marine Goujon Matthieu Jung Stéphanie Le Gras Victoria Gomez-Murcia Emilie Faivre Julie Lemaire Anne Garat Nicolas Beauval Patrice Maboudou Viviane Gnemmi Jean-Baptiste Gibier Luc Buée Corinne Abbadie Francois Glowacki Nicolas Pottier Michael Perrais Rodrigo A. Cunha Jean-Sébastien Annicotte Geoffroy Laumet David Blum Christelle Cauffiez |
| container_volume |
132 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Edmone Dewaeles |
| author2-role |
verfasserin |
| title_sort |
istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects |
| title_auth |
Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects |
| abstract |
Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. |
| abstractGer |
Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. |
| abstract_unstemmed |
Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2006 GBV_ILN_2014 GBV_ILN_2021 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
| container_issue |
22 |
| title_short |
Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects |
| url |
https://doaj.org/article/f322febb20a9426fac11bb1c684e29af https://doi.org/10.1172/JCI152924 https://doaj.org/toc/1558-8238 |
| remote_bool |
true |
| author2 |
Kévin Carvalho Sandy Fellah Jaewon Sim Nihad Boukrout Raphaelle Caillierez Hariharan Ramakrishnan Cynthia Van der Hauwaert Jhenkruthi Vijaya Shankara Nathalie Martin Noura Massri Agathe Launay Joseph K. Folger Clémentine de Schutter Romain Larrue Ingrid Loison Marine Goujon Matthieu Jung Stéphanie Le Gras Victoria Gomez-Murcia Emilie Faivre Julie Lemaire Anne Garat Nicolas Beauval Patrice Maboudou Viviane Gnemmi Jean-Baptiste Gibier Luc Buée Corinne Abbadie Francois Glowacki Nicolas Pottier Michael Perrais Rodrigo A. Cunha Jean-Sébastien Annicotte Geoffroy Laumet David Blum Christelle Cauffiez |
| author2Str |
Kévin Carvalho Sandy Fellah Jaewon Sim Nihad Boukrout Raphaelle Caillierez Hariharan Ramakrishnan Cynthia Van der Hauwaert Jhenkruthi Vijaya Shankara Nathalie Martin Noura Massri Agathe Launay Joseph K. Folger Clémentine de Schutter Romain Larrue Ingrid Loison Marine Goujon Matthieu Jung Stéphanie Le Gras Victoria Gomez-Murcia Emilie Faivre Julie Lemaire Anne Garat Nicolas Beauval Patrice Maboudou Viviane Gnemmi Jean-Baptiste Gibier Luc Buée Corinne Abbadie Francois Glowacki Nicolas Pottier Michael Perrais Rodrigo A. Cunha Jean-Sébastien Annicotte Geoffroy Laumet David Blum Christelle Cauffiez |
| ppnlink |
316004677 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| up_date |
2024-07-03T18:04:24.159Z |
| _version_ |
1803582034845630464 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ091037751</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240413222748.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240412s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ091037751</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJf322febb20a9426fac11bb1c684e29af</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Edmone Dewaeles</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Istradefylline protects from cisplatin-induced nephrotoxicity and peripheral neuropathy while preserving cisplatin antitumor effects</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cisplatin is a potent chemotherapeutic drug that is widely used in the treatment of various solid cancers. However, its clinical effectiveness is strongly limited by frequent severe adverse effects, in particular nephrotoxicity and chemotherapy-induced peripheral neuropathy. Thus, there is an urgent medical need to identify novel strategies that limit cisplatin-induced toxicity. In the present study, we show that the FDA-approved adenosine A2A receptor antagonist istradefylline (KW6002) protected from cisplatin-induced nephrotoxicity and neuropathic pain in mice with or without tumors. Moreover, we also demonstrate that the antitumoral properties of cisplatin were not altered by istradefylline in tumor-bearing mice and could even be potentiated. Altogether, our results support the use of istradefylline as a valuable preventive approach for the clinical management of patients undergoing cisplatin treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nephrology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kévin Carvalho</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandy Fellah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jaewon Sim</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nihad Boukrout</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Raphaelle Caillierez</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hariharan Ramakrishnan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Cynthia Van der Hauwaert</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jhenkruthi Vijaya Shankara</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nathalie Martin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Noura Massri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Agathe Launay</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Joseph K. Folger</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Clémentine de Schutter</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Romain Larrue</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ingrid Loison</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Marine Goujon</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matthieu Jung</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stéphanie Le Gras</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Victoria Gomez-Murcia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Emilie Faivre</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Julie Lemaire</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anne Garat</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicolas Beauval</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Patrice Maboudou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Viviane Gnemmi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jean-Baptiste Gibier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luc Buée</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Corinne Abbadie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Francois Glowacki</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicolas Pottier</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Michael Perrais</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rodrigo A. Cunha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jean-Sébastien Annicotte</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Geoffroy Laumet</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">David Blum</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Christelle Cauffiez</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">The Journal of Clinical Investigation</subfield><subfield code="d">American Society for Clinical Investigation, 2022</subfield><subfield code="g">132(2022), 22</subfield><subfield code="w">(DE-627)316004677</subfield><subfield code="w">(DE-600)2018375-6</subfield><subfield code="x">15588238</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:132</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:22</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/f322febb20a9426fac11bb1c684e29af</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1172/JCI152924</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1558-8238</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">132</subfield><subfield code="j">2022</subfield><subfield code="e">22</subfield></datafield></record></collection>
|
| score |
7.402669 |